Biofourmis Connect: Connecting drug development to care delivery
Powered by our innovative technology platform, Biofourmis offers connected, configurable, and individualized care options, managed both virtually and in-person for patients at home. For healthcare providers and risk-bearing entities, we improve clinical, operational, and economic outcomes across the care continuum.
Digital clinical trials
Our technology-enabled, scalable clinical research platform supports trial decentralization, precision participant recruitment, and equitable access to treatment options for patients everywhere*.
Our partners can:
Accelerate recruitment and raise rates of research participation through our growing global network of health system partners and sites
Ease patient burden and improve retention with digital patient engagement tools, and integrated in-home healthcare delivery and study visits
Accelerate clinical development with remote data collection and novel digital endpoints from our library of biomarkers across multiple therapeutic areas
Monitor and manage side effects, adverse events, and other safety concerns
Collect real-world evidence to inform R&D, commercial decision making, and lifecycle line extension
Digital drug companions
We help our partners develop and commercialize novel digital companion technologies that enhance traditional drug therapies, such as digital biomarkers that track pain or identify cardiac events1,2.
By studying the efficacy and expanding the use of these advances, our partners accumulate evidence and market differentiation for their products through:
Developing and integrating digital biomarkers and SaMD into established care pathways
Monitoring and management of side effects, adverse events, and other safety concerns to mitigate risk and enable patients to avoid hospital stays during therapy
Algorithm-guided recommendations for therapy titration and dose optimization based on individual’s data and baseline to drive precision medicine delivery
Digital patient engagement programs for personalized condition management and improved patient adherence
Market access solutions
We offer care pathway integration for approved therapies to help ensure that patients have access to the right treatment when and where they need it.
Our partners benefit from:
Patient identification through our growing network of health system partners to find therapy candidates and to drive both clinical and commercial outcomes
Integration into our disease-specific dynamic care pathways to optimize care delivery
Virtual visits and digital patient support programs to drive patient adherence to therapeutic protocols
In-home therapy administration, monitoring, and services with Biofourmis Care
Observational data and surveillance to support FDA post-market drug safety monitoring
Interested in learning more?
Scale and precision
Just as we carefully gather and track biomarker data on every patient, we also study the results our partners have achieved using our technology.
global clinical trial results our partners have achieved using our technology
countries with clinical trial participants
increase in usage and dosage optimization of heart failure medication3
Access and engagement
Biofourmis patients typically report a 98+% level of satisfaction with our services3. The opportunity to participate in trials and manage their medications from home helps deliver a better patient experience. Our goal is to improve their quality of life in even more ways:
Without geographic and economic barriers, a more diverse patient pool can take part in clinical trials and receive the care they need
Remote patient management helps maintain protocol adherence and identify clinical deviations, improving patient experience and safety
Virtual visits from health and wellness professionals along with coordinated digital patient experience programs offer timely education and guidance on the patient’s specific condition
Reduced travel costs and time to clinics and trial sites for patients and caregivers
Increased patient engagement via daily personal care plans, progress tracking, and ongoing patient-specific education
3. Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction, Akshay S. Desai, MD1,2; Taylor Maclean, MS1; Alexander J. Blood, MD1,2; et al,, JAMA Cardiol. 2020;5(12):1430-1434. doi:10.1001/jamacardio.2020.3757.
4. Biofourmis data on file.
*Subject to geography and connectivity